| Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia Y Herishanu, I Avivi, A Aharon, G Shefer, S Levi, Y Bronstein, M Morales, ... Blood, The Journal of the American Society of Hematology 137 (23), 3165-3173, 2021 | 621 | 2021 |
| Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups CL Batlevi, F Sha, A Alperovich, A Ni, K Smith, Z Ying, JD Soumerai, ... Blood cancer journal 10 (7), 74, 2020 | 130 | 2020 |
| Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma AJ Moskowitz, G Shah, H Schöder, N Ganesan, E Drill, H Hancock, ... Journal of Clinical Oncology 39 (28), 3109-3117, 2021 | 129 | 2021 |
| Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies D Sermer, C Batlevi, ML Palomba, G Shah, RJ Lin, MA Perales, M Scordo, ... Blood advances 4 (19), 4669-4678, 2020 | 89 | 2020 |
| Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies R Stuver, GL Shah, NS Korde, LE Roeker, AR Mato, CL Batlevi, DJ Chung, ... Cancer cell 40 (6), 590-591, 2022 | 85 | 2022 |
| Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small … JD Soumerai, AR Mato, A Dogan, VE Seshan, E Joffe, K Flaherty, J Carter, ... The Lancet Haematology 8 (12), e879-e890, 2021 | 77 | 2021 |
| Evaluation of a problem-specific SBAR tool to improve after-hours nurse-physician phone communication: a randomized trial E Joffe, JP Turley, KO Hwang, TR Johnson, CW Johnson, EV Bernstam The Joint Commission Journal on Quality and Patient Safety 39 (11), 495-AP6, 2013 | 67 | 2013 |
| Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma S Borchmann, E Joffe, CH Moskowitz, AD Zelenetz, A Noy, CS Portlock, ... Blood, The Journal of the American Society of Hematology 133 (20), 2121-2129, 2019 | 54 | 2019 |
| Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era S Bobillo, E Joffe, JA Lavery, D Sermer, P Ghione, A Noy, PC Caron, ... Blood, The Journal of the American Society of Hematology 137 (1), 39-48, 2021 | 48 | 2021 |
| Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse S Bobillo, E Joffe, D Sermer, P Mondello, P Ghione, PC Caron, ... Blood cancer journal 11 (6), 113, 2021 | 47 | 2021 |
| The value of electrophysiologic study in decision-making regarding the need for pacemaker implantation after TAVI O Tovia-Brodie, Y Ben-Haim, E Joffe, A Finkelstein, A Glick, R Rosso, ... Journal of Interventional Cardiac Electrophysiology 48, 121-130, 2017 | 43 | 2017 |
| A benchmark comparison of deterministic and probabilistic methods for defining manual review datasets in duplicate records reconciliation E Joffe, MJ Byrne, P Reeder, JR Herskovic, CW Johnson, AB McCoy, ... Journal of the American Medical Informatics Association 21 (1), 97-104, 2014 | 42 | 2014 |
| The value of PET/CT in detecting bone marrow involvement in patients with follicular lymphoma C Perry, H Lerman, E Joffe, N Sarid, O Amit, I Avivi, M Kesler, J Ben-Ezra, ... Medicine 95 (9), e2910, 2016 | 38 | 2016 |
| C-reactive protein velocity following antibiotics in patients with chronic obstructive pulmonary disease exacerbation and community acquired pneumonia D Justo, S Lachmi, N Saar, E Joffe, L Atzmony, N Mashav, O Henis, ... European journal of internal medicine 20 (5), 518-521, 2009 | 31 | 2009 |
| Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay AM Intlekofer, E Joffe, CL Batlevi, P Hilden, J He, VE Seshan, AD Zelenetz, ... Blood cancer journal 8 (6), 60, 2018 | 30 | 2018 |
| C-reactive protein to distinguish pneumonia from acute decompensated heart failure E Joffe, D Justo, N Mashav, M Swartzon, H Gur, S Berliner, Y Paran Clinical biochemistry 42 (16-17), 1628-1634, 2009 | 30 | 2009 |
| Duplicate patient records–implication for missed laboratory results E Joffe, CF Bearden, MJ Byrne, EV Bernstam AMIA annual symposium proceedings 2012, 1269, 2012 | 26 | 2012 |
| How we treat mature B-cell neoplasms (indolent B-cell lymphomas) M Lumish, L Falchi, BS Imber, M Scordo, G von Keudell, E Joffe Journal of Hematology & Oncology 14, 1-19, 2021 | 25 | 2021 |
| Positron-emission tomography–based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma CL Batlevi, F Sha, A Alperovich, A Ni, K Smith, Z Ying, JF Gerecitano, ... European Journal of Cancer 126, 78-90, 2020 | 25 | 2020 |
| Improved efficacy of tafasitamab plus lenalidomide versus systemic therapies for relapsed/refractory DLBCL: RE-MIND2, an observational retrospective matched cohort study GS Nowakowski, DH Yoon, A Peters, P Mondello, E Joffe, I Fleury, R Greil, ... Clinical Cancer Research 28 (18), 4003-4017, 2022 | 24 | 2022 |
